| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
|
Blood
|
2004
|
1.82
|
|
2
|
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.82
|
|
3
|
Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
|
J Clin Oncol
|
2013
|
1.50
|
|
4
|
ABT-737 is highly effective against molecular subgroups of multiple myeloma.
|
Blood
|
2011
|
1.35
|
|
5
|
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
|
Blood
|
2005
|
1.23
|
|
6
|
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.
|
Blood
|
2008
|
1.21
|
|
7
|
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
|
J Clin Oncol
|
2009
|
1.21
|
|
8
|
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study.
|
J Acquir Immune Defic Syndr
|
2013
|
1.18
|
|
9
|
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.
|
Oncogene
|
2005
|
1.15
|
|
10
|
Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.14
|
|
11
|
Lack of CD27 in myeloma delineates different presentation and outcome.
|
Br J Haematol
|
2006
|
1.10
|
|
12
|
Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.
|
Am J Surg Pathol
|
2009
|
1.09
|
|
13
|
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
|
Cancer Res
|
2012
|
1.08
|
|
14
|
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2010
|
1.08
|
|
15
|
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?
|
Eur J Nucl Med Mol Imaging
|
2009
|
1.07
|
|
16
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
|
J Clin Oncol
|
2012
|
1.03
|
|
17
|
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.
|
Blood
|
2006
|
1.03
|
|
18
|
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2009
|
1.01
|
|
19
|
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
|
Cancer
|
2014
|
1.00
|
|
20
|
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
|
Mol Cancer Ther
|
2009
|
1.00
|
|
21
|
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.99
|
|
22
|
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.98
|
|
23
|
The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.
|
Br J Haematol
|
2011
|
0.97
|
|
24
|
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
|
Oncogene
|
2005
|
0.97
|
|
25
|
ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
|
Clin Cancer Res
|
2011
|
0.96
|
|
26
|
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
|
Haematologica
|
2011
|
0.93
|
|
27
|
Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
|
Haematologica
|
2008
|
0.92
|
|
28
|
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
|
Haematologica
|
2010
|
0.91
|
|
29
|
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
|
Haematologica
|
2010
|
0.88
|
|
30
|
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
|
Leuk Lymphoma
|
2014
|
0.86
|
|
31
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
|
Haematologica
|
2013
|
0.84
|
|
32
|
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
|
Ann Hematol
|
2013
|
0.84
|
|
33
|
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
|
Biol Blood Marrow Transplant
|
2013
|
0.84
|
|
34
|
Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?
|
Transplantation
|
2012
|
0.84
|
|
35
|
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.
|
Blood Cells Mol Dis
|
2012
|
0.83
|
|
36
|
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2010
|
0.83
|
|
37
|
Mantle cell lymphoma epidemiology: a population-based study in France.
|
Ann Hematol
|
2014
|
0.83
|
|
38
|
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
|
Eur J Haematol
|
2013
|
0.82
|
|
39
|
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
|
Leuk Lymphoma
|
2011
|
0.81
|
|
40
|
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
|
Biol Blood Marrow Transplant
|
2011
|
0.81
|
|
41
|
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
|
Leuk Lymphoma
|
2010
|
0.80
|
|
42
|
18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease.
|
Haematologica
|
2008
|
0.79
|
|
43
|
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
|
Leuk Lymphoma
|
2014
|
0.78
|
|
44
|
Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.
|
Leuk Lymphoma
|
2015
|
0.78
|
|
45
|
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
46
|
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
|
Haematologica
|
2008
|
0.76
|
|
47
|
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
|
BMC Cancer
|
2014
|
0.76
|
|
48
|
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
|
Ann Hematol
|
2014
|
0.75
|
|
49
|
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
|
Br J Haematol
|
2013
|
0.75
|
|
50
|
Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
|
Br J Haematol
|
2012
|
0.75
|
|
51
|
Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.
|
Expert Rev Hematol
|
2015
|
0.75
|
|
52
|
Thoracic subcutaneous infiltration: an unusual presentation of subcutaneous panniculitis-like T-cell lymphoma.
|
Acta Derm Venereol
|
2009
|
0.75
|
|
53
|
High-dose chemotherapy followed by autologous stem-cell transplantation in liver-transplanted multiple myeloma patients: a report of two cases.
|
Transplantation
|
2009
|
0.75
|